Effect of Uterine Leiomyomas on Noninvasive Prenatal Testing Parameters in the First Trimester

Obstet Gynecol. 2024 Mar 1;143(3):456-458. doi: 10.1097/AOG.0000000000005504. Epub 2024 Jan 11.

Abstract

Uterine leiomyomas may affect the performance of cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). We conducted a retrospective cohort study of pregnant individuals with and without leiomyomas undergoing first-trimester cfDNA-based NIPT. Characteristics of NIPT in patients with leiomyomas (n=122) were compared with those in patients without leiomyomas (n=937). Mean fetal fraction was lower in patients with leiomyomas compared with patients without (10.0% vs 11.5%; P =.001); however, the rate of indeterminate results was different only in patients without obesity (body mass index [BMI] lower than 30) (5.3% vs 1.5%; P =0.03). Total cfDNA concentration was higher in patients with leiomyomas ( P =.002), suggesting possible dilution of the fetal fraction. Leiomyoma size did not affect NIPT metrics. In conclusion, uterine leiomyomas are associated with lower fetal fraction and, in patients without obesity, with a higher rate of indeterminate results independent of leiomyoma size.

MeSH terms

  • Cell-Free Nucleic Acids*
  • Female
  • Humans
  • Leiomyoma* / diagnosis
  • Noninvasive Prenatal Testing*
  • Obesity
  • Pregnancy
  • Pregnancy Trimester, First
  • Prenatal Diagnosis / methods
  • Retrospective Studies

Substances

  • Cell-Free Nucleic Acids